NICE guidance on bevacizumab in combination with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer

摘要

On May 22, 2013, the National Institute for Health and Care Excellence (NICE) published guidance on bevacizumab in combination with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer.Bevacizumab was appraised under the Single Technology Appraisal process. The manufacturer (Roche Products, Welwyn Garden City, UK) submitted evidence for the clinical effectiveness and cost-effectiveness of bevacizumab, which was reviewed by an independent Evidence Review Group (ERG), Southampton Health Technology Assessments Centre.